159 related articles for article (PubMed ID: 15068607)
1. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody.
Vallera DA; Elson M; Brechbiel MW; Dusenbery KE; Burns LJ; Jaszcz WB; Ramsay NK; Panoskaltsis-Mortar A; Kuroki DW; Wagner JE; Vitetta ES; Kersey JH
Cancer Biother Radiopharm; 2004 Feb; 19(1):11-23. PubMed ID: 15068607
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice.
Vallera DA; Elson M; Brechbiel MW; Dusenbery KE; Burns LJ; Skubitz KM; Jaszcz WB; Ramsay NK; Panoskaltsis-Mortari A; Kuroki DW; Wagner JE; Kersey JH
Cancer Biother Radiopharm; 2003 Apr; 18(2):133-45. PubMed ID: 12804039
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
5. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
6. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
7. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody.
Vallera DA; Sicheneder AR; Taras EP; Brechbiel MW; Vallera JA; Panoskaltsis-Mortari A; Burns LJ
Cancer Biother Radiopharm; 2007 Aug; 22(4):488-500. PubMed ID: 17803443
[TBL] [Abstract][Full Text] [Related]
9. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
10. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.
Roselli M; Milenic DE; Brechbiel MW; Mirzadeh S; Pippin CG; Gansow OA; Colcher D; Schlom J
Cancer Biother Radiopharm; 1999 Jun; 14(3):209-20. PubMed ID: 10850305
[TBL] [Abstract][Full Text] [Related]
11. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
12. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
[TBL] [Abstract][Full Text] [Related]
13. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
14. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
16. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
[TBL] [Abstract][Full Text] [Related]
17. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
[TBL] [Abstract][Full Text] [Related]
18. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
Vallera DA; Schmidberger H; Buchsbaum DJ; Everson P; Snover DC; Blazar BR
Cancer Res; 1991 Apr; 51(7):1891-7. PubMed ID: 2004372
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]